SCHEDULE 13G - Scienture Holdings, Inc. (0001382574) (Subject)

8-K - Scienture Holdings, Inc. (0001382574) (Filer)

424B5 - Scienture Holdings, Inc. (0001382574) (Filer)

10-Q - Scienture Holdings, Inc. (0001382574) (Filer)

EFFECT - Scienture Holdings, Inc. (0001382574) (Filer)

D/A - Scienture Holdings, Inc. (0001382574) (Filer)

S-3 - Scienture Holdings, Inc. (0001382574) (Filer)

D - Scienture Holdings, Inc. (0001382574) (Filer)

8-K - Scienture Holdings, Inc. (0001382574) (Filer)

1-A-W - Scienture Holdings, Inc. (0001382574) (Filer)

Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (NASDAQ:SCNX) ("Scienture" or the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 3,225,000 shares of common stock at an offering price of $1.20 per share, in a registered direct offering. The gross proceeds for the offering are expected to be approximately $3.9 million bef

COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the shipment of launch quantities of Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL to its 3PL/Distribution Center for the intended commercial launch of the product. This shipment marks a major milestone accomplishment for Scienture, which has agreements in place for the distribution of the product through wholesa

Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its board of directors has approved a bridge funding raise of up to an aggregate amount of $3 million, of which it has secured approximately $1.2 million, through the issuance of shares of the Company's common stock to institutional or accredited investors. The bridge funding does not include any other obli

Commack, NY, July 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has received a notification letter from The Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of the Company's common stock has been at $1.00 per share or greater for the previous ten consecutive business days. As

TAMPA, FL, June 17, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, announced it has terminated its Equity Line of Credit ("ELOC") facility effective as of May 22, 2025. In connection with cancellation of the ELOC, on June 16, 2025, the Company filed a post-effective amendment to the Registration Statement on Form S-1 (File No. 333-283591) filed with the Securities and Exchange Commission on Dec

TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani. Shankar Hariharan, P

TAMPA, FL, May 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that the U.S. Food and Drug Administration (FDA) has listed U.S. Patent Nos. 11890273 (the ‘273 patent) and 12156869 (the '869 patent), each with an expiration date of October 2041, in its Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) for Arbli™, (losartan potassium) Ora

TAMPA, FL, April 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the initiation of supply chain activities by its wholly owned subsidiary Scienture, LLC to manufacture launch quantities of ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL for the intended commercial launch of the product in July 2025. Scirenture, LLC's contract manufacturing partner, Saptalis Pharmaceuticals, LLC

TAMPA, FL, April 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, announced the divestiture of its legacy Healthcare IT and Wholesale Operations subsidiaries Integra Pharma Solutions (IPS), Bonum Health, Inc., and Softell, Inc. to Tollo Health, Inc. for a total consideration of $5 million. The divestitures are part of a broader strategic realignment at the Company designed to sharpen operatio

TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to provide this annual update from its Chief Executive Officer, Surendra Ajjarapu, to its stockholders. This time last year, Scienture Holdings, Inc. (f.k.a. TRxADE Health, Inc.). was focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. The primary operations were conducted through

TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani. Shankar Hariharan, P